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Abstract
Purpose To provide additional clinical data about the re-irradiation tolerance of the spinal cord.
Methods This was a retrospective bi-institutional study of patients re-irradiated to the cervical or thoracic spinal cord
with minimum follow-up of 6 months. The maximum dose (Dmax) and dose to 0.1cc (D0.1cc) were determined (magnetic
resonance imaging [MRI]-defined cord) and expressed as equivalent dose in 2-Gy fractions (EQD2) with an α/β value of
2Gy.
Results All 32 patients remained free from radiation myelopathy after a median follow-up of 12 months. Re-irradiation
was performed after 6–97 months (median 15). In 22 cases (69%) the re-irradiation spinal cord EQD2 Dmax was higher
than that of the first treatment course. Forty-eight of 64 treatment courses employed fraction sizes of 2.5 to 4Gy to the
target volume. The median cumulative spinal cord EQD2 Dmax was 80.7Gy, minimum 61.12Gy, maximum 114.79Gy. The
median cumulative spinal cord D0.1cc EQD2 was 76.1Gy, minimum 61.12Gy, maximum 95.62Gy. Besides cumulative
dose, other risk factors for myelopathy were present (single-course Dmax EQD2 ≥51Gy in 9 patients, single-course D0.1cc
EQD2 ≥51Gy in 5 patients).
Conclusion Even patients treated to higher cumulative doses than previously recommended, or at a considerable risk of
myelopathy according to a published risk score, remained free from this complication, although one must acknowledge the
potential for manifestation of damage in patients currently alive, i.e., still at risk. Individualized decisions to re-irradiate
after appropriate informed consent are an acceptable strategy, including scenarios where low re-irradiation doses to the
spinal cord would compromise target coverage and tumor control probability to an unacceptable degree.
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Introduction
Experimental animal data have suggested that spinal cord
re-irradiation is a feasible approach [1, 2]. In clinical prac-
tice, several treatment planning and delivery techniques al-
low for sparing of the spinal cord [3–8]. However, it is not
always possible to avoid limited re-irradiation doses, and
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sometimes high-dose re-irradiation is the only treatment
option [9]. A simple method for calculating re-irradiation
tolerance is to assume time-dependent recovery (25% af-
ter 6 months, 50% after 12 months), resulting in tolerance
doses of 125% and 150%, respectively [10]. For example,
an initial treatment course that resulted in an equivalent
2 Department of Radiation Oncology, Kindai
University Faculty of Medicine, 377-2
Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan
3 Department of Radiation Oncology, Osaka
University Graduate School of Medicine, 2-2
Yamadaoka, Suita, Osaka 565-0871, Japan
4 Department of Oncology and Palliative Medicine, Nordland
Hospital Trust, 8092 Bodø, Norway
5 Department of Clinical Medicine, Faculty of Health Sciences,
UiT—The Arctic University of Norway, Tromsø, Norway
K
464 Strahlenther Onkol (2021) 197:463–473
Table 1 Risk factors for radiation myelopathy after re-irradiation
Risk factor Characteristic Points
Time interval <6 months 4.5
≥6 months 0
EQD2 for first or second course ≥51Gy 4.5
EQD2 for both courses <51Gy 0






EQD2 equivalent dose in 2-Gy fractions. For doses >90Gy the same
principle of adding one point per dose interval applies. Low risk: point
sum 0-3, intermediate risk: point sum 4–6, high risk: point sum >6.
spinal cord dose (EQD2) close to 50Gy in 2-Gy fractions
may be supplemented by a second course with spinal cord
EQD2 of 25Gy in 2-Gy fractions 18 months later, i.e., 50%
of the tolerance dose in the first-line setting. For occasional
patients, such limited re-irradiation doses are not sufficient
to achieve the desired outcome in terms of efficacy or local
control [11]. A myelopathy risk score has been developed to
inform treatment planning decisions under these special cir-
cumstances. The development cohort included 40 individual
patients from eight different publications, and 11 of these
patients had developed radiation myelopathy [12]. Later,
38 additional patients treated by the authors of that report or
published in four different other publications were studied
[13]. The risk score based on three variables (cumulative
equivalent dose, highest equivalent dose of all treatment
series in a particular individual, and time interval between
first and second course), which discriminates three differ-
ent risk groups, did not require modification after evalu-
ation of these 38 new patients. Still <5% of the patients
in the low-risk group had developed radiation myelopathy.
A recent publication from Japan (74 patients) has provided
additional clinical data [14]. In the present bi-institutional
study, all Japanese data fulfilling certain eligibility criteria
were pooled with new data collected by the first author of
the risk score in order to confirm the safety of the previous
recommendations. Neither institution has encountered any
case of re-irradiation myelopathy in the cervical or thoracic
spine so far.
Materials andmethods
For the present retrospective study, the Japanese authors
provided expanded individual patient data that originated
from their previous publication [14]. The Norwegian data,
which have not been published previously, were extracted
and converted to EQD2 according to the same methods.
The Institutional Review Board at Miyakojima IGRT clinic
approved the study. Only patients who were followed for at
least 6 months from re-irradiation to the cervical or thoracic
spinal cord were eligible. The follow-up information, e.g.,
clinical symptoms of radiation myelopathy, was obtained
from the institutional electronic patient records. Re-irradi-
ation was performed in the time period between 2007 and
2018, with different treatment planning systems and linear
accelerators in use. Image guidance, e.g., cone beam com-
puted tomography (CBCT), was not mandatory. Fractiona-
tion and total dose were at the discretion of the treating team
of radiation oncologists and physicists. Spinal cord EQD2
was calculated according to the linear-quadratic model with
an α/β value of 2Gy [15, 16], based on the dose–volume
histograms of the three-dimensional treatment plans where
the true spinal cord had been contoured, as opposed to sur-
rogate structures such as the spinal canal. Both maximum
dose (Dmax) and dose to 0.1 cc (D0.1cc) of the re-irradi-
ated spinal cord were tabulated. In case of two-dimensional
treatment techniques, spinal cord doses were reconstructed
on fused computed tomography (CT) and magnetic reso-
nance imaging (MRI) scans. Coregistered treatment plan-
ning scans from the first and second courses were used to
assess the cumulative doses in the overlapping region. The
risk score was calculated as described previously [12, 13]
(displayed in Table 1).
Results
Sixteen adult patients received re-irradiation at the Nor-
wegian center and 16at the Japanese center. All 32 pa-
tients were re-irradiated to the cervical or thoracic spinal
cord and were followed for at least 6 months from re-ir-
radiation (median 12 months, maximum 90 months), Ta-
ble 2. The median age was 60.5 years. Twenty-four patients
(75%) were re-irradiated for bone metastases (diagnosis
code C79.5). Other indications included multiple myeloma,
leptomeningeal spinal metastases, and intrathoracic primary
tumors, among others. The most common primary tumors
were lung cancer (C34.9) in 10 patients (31%), hepatic can-
cer (19%), and kidney cancer (12.5%). Re-irradiation was
performed after 6–97 months (median 15). The cervical
cord was re-irradiated in 9 patients (28%), including those
with treatment of the cervicothoracic region such as level
C7-Th2. A single vertebra was re-irradiated in 12 patients
(37.5%), two in 9 patients (28%), and three or more in
11 patients (34%).
The most common fractionation regimen was 10 frac-
tions of 3Gy (21 of 64 treatment courses, 33%). Forty-
eight of 64 treatment courses (75%) employed fraction sizes
of 2.5 to 4Gy to the target volume. In 22 cases (69%),
the re-irradiation spinal cord equivalent Dmax was higher
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than that of the first treatment course. In most cases, Dmax
was similar to D0.1cc (difference within 5%); however, in
15 of 64 treatment courses (23%) larger differences were
registered, in line with the fact that many Japanese pa-
tients received cord-sparing intensity-modulated radiother-
apy (IMRT), whereas the Norwegian center utilized simpler
techniques with more homogeneous doses throughout the
entire spinal canal.
The median cumulative spinal cord Dmax EQD2 was
80.7Gy, minimum 61.12Gy, maximum 114.79Gy. The me-
dian cumulative spinal cord D0.1cc EQD2 was 76.1Gy,
minimum 61.12Gy, maximum 95.62Gy. Besides cumula-
tive dose, other risk factors were present (single-course
Dmax EQD2 ≥51Gy in 9 patients, single-course D0.1cc
EQD2 ≥51Gy in 5 patients). The risk score (Table 1) was
calculated both for Dmax and D0.1cc. For Dmax, 12 pa-
tients (37.5%) were low risk, 8 (25%) intermediate risk, and
12 (37.5%) high risk. For D0.1cc, 14 patients (44%) were
low risk, 13 (41%) intermediate risk, and 5 (16%) high risk.
Discussion
In contrast to previous publications that mainly included
dosimetric data from the two-dimensional era without MRI-
based spinal cord contouring [12, 13, 17], the present bi-
institutional study attempted to assess the “true” spinal
cord Dmax and D0.1cc. If the actual treatment planning
did not include MRI and/or 3D dose–volume histograms,
the respective plans were calculated by the authors in the
context of this study. Ideally, the true dose–volume his-
tograms would form the basis of future recommendations.
Our group limited inclusion to patients re-irradiated to
the cervical or thoracic spine. As already discussed by
Sahgal et al. [18], the Dmax has a high degree of dose
uncertainty, and therefore other dose–volume histogram
parameters should also be analyzed. In a previous seminal
paper, Sahgal et al. compared five cases of re-irradiation-
induced myelopathy to a control group of 14 re-irradiated
patients with 16 spinal segments treated [19]. In the small
myelopathy cohort, the median EQD2 Dmax for the SBRT
component and cumulative EQD2 were 61.7Gy (range,
44.1–104.9Gy) and 99.6Gy (range, 77.2–154.9Gy), re-
spectively (α/β-value 2Gy). In the cohort without myelopa-
thy, the median EQD2 Dmax for the SBRT component
and cumulative EQD2 were 12.5Gy (range 1.9–58.7Gy)
and 52.4Gy (range 39.1–111.2Gy), respectively. For re-
irradiation SBRT delivered in 1 to 5 fractions, Sahgal
et al. have recommended that the cumulative thecal sac
EQD2 Dmax should not exceed 70Gy [19]. According to
the older risk score, 75Gy to the thecal sac would still
result in a low risk of myelopathy, as long as the time
interval is ≥6 months and neither of the two courses results
in a single-course EQD2 ≥51Gy [12, 13].
Both institutions reporting the present data chose to ex-
ceed previous recommendations in selected cases where the
administration of lower doses to the target volume was not
desirable (lack of local control) and where better cord spar-
ing could not be achieved. Of course, such individual de-
cisions require appropriate informed consent from the pa-
tients. Fortunately, radiation myelopathy has not been ob-
served after re-irradiation courses that were considered in-
termediate or high risk according to the risk score displayed
in Table 1 [12, 13]. For the low-risk group, the risk of
myelopathy was indistinguishable from that of first-line ra-
diotherapy in the previous reports (<5%) [12, 13] and zero
in the present study, which thereby validates the original
findings. If one puts aside the methodological differences
between the previous and the present reports, and chooses
to add the new intermediate-risk patients to the 8 previous
patients (2/8 had radiation myelopathy for a risk of 25%),
the new risk estimate would read 2/16 (based on Dmax) and
2/21 (based on D0.1cc), respectively. The resulting risks of
12.5 and 9.5%, respectively, would then appear lower than
previously estimated. We feel that the new results lend sup-
port to the authors’ current clinical practice of loosening
the dose constraints for spinal cord re-irradiation if lower
doses cannot be achieved, despite the limited number of
patients eligible for this study. Importantly, all excluded
patients who died within 6 months from re-irradiation or
have shorter, ongoing follow-up also remained free from
myelopathy. This finding strengthens our current policy and
leads us to believe that we are not gambling with patient
safety. The pros and cons of a conservative, low-myelopa-
thy-risk dose prescription and a possibly slightly more risky
“prioritize local control” prescription that involves higher
doses must be explained to the patients in sufficient detail.
In the Japanese re-irradiation study, which also included
patients with short follow-up and/or lumbosacral re-irradia-
tion, the 3-year local control rate was 84% [14]. This figure
is in line with other results in the literature [4].
In clinical routine, different treatment planning and de-
livery techniques should be considered when preparing
a new patient for treatment to make sure one avoids un-
necessary risks, e.g., by achieving steep dose gradients so
that only a small volume of the spinal cord receives a high
cumulative dose. It is also necessary to minimize the risk
of geographical miss, ensuring that high-dose areas do
not move in unintended ways [20]. Despite several advan-
tages of the present study compared to its predecessors,
limitations must also be considered. We acknowledge that
several of these are present, including the retrospective
design, the limited number of eligible participants, their
heterogeneous baseline and treatment characteristics, and
the uncertainty of reconstructed dose distributions. Most re-
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irradiation courses employed moderate hypofractionation
rather than typical SBRT fractionation. Of course, patients
whose follow-up is still ongoing may be at risk of radiation
myelopathy at later timepoints. Despite several experimen-
tal approaches, this severe complication, which may still be
observed in the clinic [21], is difficult to modulate pharma-
cologically [22–24]. Hopefully, our study will encourage
other institutions to publish their experiences with spinal
re-irradiation, because further research is needed to confirm
the limited tolerance data.
Conclusion
Even patients treated to higher cumulative doses than previ-
ously recommended, or at considerable risk of myelopathy
according to a published risk score, remained free from
this complication, although one must acknowledge the po-
tential for subsequent manifestation of damage in patients
currently alive, i.e., still at risk while being followed. In-
dividualized decisions to re-irradiate after appropriate in-
formed consent are an acceptable strategy, including scenar-
ios where low re-irradiation doses to the spinal cord would
compromise target coverage and tumor control probability
to an unacceptable degree.
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